Unlocking a Combination Therapy for New Onset T1D

A new study is further assessing if a novel combination of drugs could help treat new onset type 1 diabetes University of Florida researchers are ready to launch a new clinical study to examine if a combination of two U.S Food and Drug Administration (FDA) approved drugs, antithymocyte globulin (ATG) and granulocyte colony stimulating factor […]

Engineering a Better Shield for Beta Cells

Researchers discovered a protein shield that may enhance the protective barrier of encapsulated islets for type 1 diabetes A new technology for encapsulating islets or beta cells using the human protein called CXCL12 could result in improved encapsulated cell replacement therapies for individuals with type 1 diabetes (T1D). JDRF-supported researcher Dr. Mark C. Poznansky, Associate […]

A song worth more than a listen

Korn releases exclusive download to benefit T1D research What can one voice raised against type 1 diabetes (T1D) do? If you’re Jonathan Davis, lead singer of acclaimed rock band Korn, one voice can reach millions to help people living with T1D. Jonathan’s young son, Zeppelin, was diagnosed with T1D just over a year ago, and […]

Advancing a Key Artificial Pancreas Technology

Stable liquid glucagon developed by JDRF partner Xeris evaluated in first clinical study The JDRF Artificial Pancreas (AP) project is focused on accelerating the development of commercially-viable AP systems that better mimic the biological function of the pancreas and reduce the daily burden of managing type 1 diabetes (T1D). To achieve this goal, JDRF funds […]

Improving Beta Cell Health and Survival

JDRF-funded clinical study to test marketed drug to improve beta cell health and survival in T1D JDRF recently awarded a $2.1 million grant to Anath Shalev, M.D., director of the University of Alabama’s (UAB) Comprehensive Diabetes Center, to test the impact of a common blood pressure drug called verapamil on the health and survival of […]

Historic Progress for JDRF Encapsulation Research Program

First people with type 1 diabetes receive experimental encapsulated cell replacement therapies in clinical studies Two JDRF-funded partners have successfully implanted people with type 1 diabetes (T1D) with experimental encapsulated cell replacement therapies in clinical studies. These two programs are running in parallel and are evaluating two distinct encapsulation therapies. Encapsulated cell replacement therapy involves […]

A Personal Story: The Need for Medicare Coverage of Continuous Glucose Monitors (CGM)

Diabetes technologies have the potential to transform the care of people with diabetes. The continuous glucose monitor (CGM) has been shown to improve glucose control—preventing dangerous high and low blood sugars—and is recommended by national diabetes clinical guidelines and covered by private health plans. However, Medicare does not yet cover CGM devices, denying Americans age […]

It’s Time to Redefine Type 1 Diabetes

Last month, JDRF co-hosted a workshop where healthcare experts from government, nonprofit agencies and educational institutions discussed expanding the definition of Type 1 Diabetes (T1D) to recognize the earliest stages of human T1D before a person is clinically symptomatic. The benefits of the proposed system could include potentially faster drug development, identification of people living […]

Making the T1D Vaccine a Reality

Nanoparticle-based vaccine is designed to re-educate the immune system and halt the attack on the pancreas Over the last three years, Selecta Bioscience, a clinical stage biotechnology company, has been developing nanoparticles called Synthetic Vaccine Particle (SVP) as an immunotherapy for Type 1 diabetes (T1D) with support from JDRF and it was announced this week […]